Insmed Incorporated - Common Stock (INSM)

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.

The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000

Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them?

BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.